Pliant Therapeutics

Pliant Therapeutics Pliant Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics.

We’re pleased to announce that the U.S. FDA has granted Fast Track designation to PLN-101095, our oral, small molecule, ...
08/18/2026

We’re pleased to announce that the U.S. FDA has granted Fast Track designation to PLN-101095, our oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. This designation is supported by encouraging Phase 1a data demonstrating anti-tumor activity and a favorable safety profile for this combination in immune checkpoint inhibitor resistant solid tumors.

We look forward to continuing to work closely with the FDA to accelerate the development of PLN-101095.

Read the press release here: https://lnkd.in/gCkg_qw2

Excited to present FORTIFY, our ongoing Phase 1b trial, to the global oncology community at the 2026 American Society of...
05/21/2026

Excited to present FORTIFY, our ongoing Phase 1b trial, to the global oncology community at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. FORTIFY is an indication expansion trial investigating PLN-101095 in combination with pembrolizumab that is enrolling patients with certain immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Presentation details: https://lnkd.in/gm2jwWqF

Excited to announce the dosing of the first patient in our FORTIFY Phase 1b indication expansion trial. This trial is ev...
04/30/2026

Excited to announce the dosing of the first patient in our FORTIFY Phase 1b indication expansion trial. This trial is evaluating PLN-101095, our novel dual integrin inhibitor, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-refractory solid tumors.

While ICIs have transformed cancer care, approximately 70–85% of patients with solid tumors do not respond to or develop resistance to them. Read more about FORTIFY, today’s news and how Pliant is focused on addressing underserved areas of medical need: https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-announces-first-patient-dosed-fortify-phase

In an oral presentation today, UT MD Anderson Cancer Center's Dr. Timothy Yap presented updated results from our Phase 1...
04/18/2026

In an oral presentation today, UT MD Anderson Cancer Center's Dr. Timothy Yap presented updated results from our Phase 1 trial of PLN-101095 in patients with ICI-refractory solid tumors as part of the American Association for Cancer Research's 2026 Annual Meeting. Review the data and presentation https://lnkd.in/gCvrb5fQ

Address

331 Oyster Point Boulevard
South San Francisco, CA
94080

Website

Alerts

Be the first to know and let us send you an email when Pliant Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Pliant Therapeutics:

Shortcuts

Share

Category